Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders

Abstract

The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase inhibitor and another therapeutic agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, and mild cognitive impairment.

1 . A unit dosage form comprising a combination of (R)-2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt or ester thereof and an acetylcholine esterase inhibitor or a pharmaceutically acceptable salt or ester thereof.  
     
     
         2 . The unit dosage form of  claim 1  wherein said acetylcholine esterase inhibitor is rivastigmine.  
     
     
         3 . The unit dosage form of  claim 1  wherein (R)-2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt or ester thereof is present in an amount from 100 mg to 1000 mg.  
     
     
         4 . The unit dosage form of  claim 2  wherein rivastigmine or a pharmaceutically acceptable salt or ester thereof is present in an amount from 1 to 15 mg.  
     
     
         5 . The unit dosage form of  claim 1  wherein (R)-2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt or ester thereof is present in an amount from 200 mg to 800 mg.  
     
     
         6 . The unit dosage form of  claim 2  wherein rivastigmine or a pharmaceutically acceptable salt or ester thereof is present in an amount from 3 mg to 12 mg.  
     
     
         7 . The unit dosage form of  claim 1  wherein (R)-2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt or ester thereof is present in an amount from 300 mg to 500 mg.  
     
     
         8 . The unit dosage form of  claim 2  wherein rivastigmine or a pharmaceutically acceptable salt or ester thereof is present in an amount from 3 mg to 6 mg.  
     
     
         9 . The unit dosage form according to  claim 1  wherein said unit dosage form is chosen from a tablet, a capsule, and a caplet.  
     
     
         10 . The unit dosage form according to  claim 1  further comprising microcrystalline cellulose.  
     
     
         11 . A method of treating mild Alzheimer's disease in an individual comprising identifying an individual having mild Alzheimer's disease and administering to the individual an Alzheimer's disease treating effective amount of (R)-2-(2-fluoro-4-biphenylyl)propionic acid or a pharmaceutically acceptable salt or ester thereof and an acetylcholine esterase inhibitor or a pharmaceutically acceptable salt or ester thereof.  
     
     
         12 . The method of  claim 11  wherein the acetylcholine esterase inhibitor is a rivastigmine.  
     
     
         13 . The method of 12 wherein rivastigmine and (R)-2-(2-fluoro-4-biphenylyl)propionic acid are co-formulated.  
     
     
         14 . The method of  claim 12  wherein rivastigmine and (R)-2-(2-fluoro-4-biphenylyl)propionic acid are co-administered.  
     
     
         15 . The method of  claim 12  wherein said individual is titrated to a stable dose of rivastigmine prior to treatment with (R)-2-(2-fluoro-4-biphenylyl)propionic acid.  
     
     
         16 . The method of  claim 12  wherein 3 mg to 15 mg of rivastigmine, or a pharmaceutically acceptable salt or ester, thereof is administered per day.  
     
     
         17 . The method of  claim 12  wherein 12 mg of rivastigmine, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         18 . The method of  claim 12  wherein 6 mg of rivastigmine, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         19 . The method of  claim 12  wherein 400 or more mg of (R)-2-(2-fluoro-4-biphenylyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         20 . The method of  claim 12  wherein 600 or more mg of (R)-2-(2-fluoro-4-biphenylyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         21 . The method of  claim 12  wherein 800 or more mg of (R)-2-(2-fluoro-4-biphenylyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         22 . The method of  claim 12  wherein 1600 or more mg of (R)-2-(2-fluoro-4-biphenylyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, is administered per day.  
     
     
         23 . A co-formulation comprising a first compound which is rivastigmine or a pharmaceutically acceptable salt or ester thereof and a second compound which is an Aβ42 lowering agent or a pharmaceutically acceptable salt or ester thereof.  
     
     
         24 . The co-formulation of  claim 23  wherein said Aβ42 lowering agent is chosen from 5 [1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-2H-tetrazole, 2-(4-isobutyl-phenyl)-2-methyl propionic acid, 2-(2-fluoro-1,1′-biphenyl-4-yl)-2-methylpropionic acid, 2-methyl-2 (2-fluoro-4′-trifluoromethylbiphen-4-yl) propionic acid, 2-methyl-2 (2-fluoro-4′cyclohexyl biphen-4-yl) propionic acid, 1-(2-fluoro-4′-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(4′-cyclohexyl-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(4′-benzyloxy-2-fluorobiphenyl-4-yl) cyclopropanecarboxylic acid, 1-(2-fluoro-4′-isopropyloxybiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(2-fluoro-3′-trifluoromethoxybiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(2-fluoro-4′-trifluoromethoxybiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(2-fluoro-3′-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(4′-cyclopentyl-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(4′-cycloheptyl-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(2′-cyclohexyl-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(2-fluoro-4′-hydroxybiphenyl-4-yl)cyclopropanecarboxylic acid, 1-[2-fluoro-4′-(tetrahydropyran-4-yloxy) biphenyl-4-yl]-cyclopropane-carboxylic acid, 1-(2,3′,4′-trifluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(3′,5′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid 1-(3′-chloro-2,4′-difluorobiphenyl-4-yl)cyclopropanecarboxylic acid, 1-(4-benzo[b]thiophen-3-yl-3-fluorophenyl)cyclopropanecarboxylic acid, 1-(2-fluoro-4′-prop-2-inyloxy-biphenyl-4-yl)-cyclopropanecarboxylic acid, 1-(4′-cyclohexyloxy-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, 1-[2-fluoro-4′-(tetrahydropyran-4-yl)-biphenyl-4-yl]-cyclopropanecarboxylic acid, 1-[2-fluoro-4′-(4-oxo-cyclohexyl)-biphenyl-4-yl]-cyclopropanecarboxylic acid, 2-(2″-fluoro-4-hydroxy-[1,1′:4′,1″]tert-phenyl-4″-yl)-cyclopropanecarboxylic acid, 1-[4′-(4,4-dimethylcyclohexyl)-2-fluoro[1,1′-biphenyl]-4-yl]-cyclopropane-carboxylic acid, 1-[2-fluoro-4′-[[4-(trifluoromethyl)benzoyl]ammino][1,1′-biphenyl]-4-yl]-cyclopropanecarboxylic acid, 1-[2-fluoro-4′-[[4-(trifluoromethyl)cyclohexyl]oxy][1,1′-biphenyl]-4-yl]-cyclopropanecarboxylic acid, 1-[2-fluoro-4′-[(3,3,5,5-tetramethylcyclohexyl) oxy][1,1′-biphenyl]-4-yl]-cyclopropanecarboxylic acid, 1-[4′-[(4,4-dimethylcyclohexyl) oxy]-2-fluoro[1,1′-biphenyl]-4-yl]-cyclopropanecarboxylic acid, 1-(2,3′, 4″-trifluoro[1,1′:4′,1″-tert-phenyl]-4-yl)-cyclopropanecarboxylic acid, 1-(2,2′, 4″-trifluoro[1,1′:4′,1″-tert-phenyl]-4-yl)-cyclopropanecarboxylic acid, 1-(2,3′-difluoro-4″-hydroxy[1,1′:4′,1″-tert-phenyl]-4-yl)-cyclopropane-carboxylic acid, 1-(2,2′-difluoro-4″-hydroxy[1,1′:4′,1″-tert-phenyl]-4-yl)-cyclopropane-carboxylic acid, 2-(2-fluoro-3′,5′-bis(chloro) biphen-4-yl) propionic acid amide, 2-(2-fluoro-4′-trifluoromethylbiphen-4-yl) propionic acid, 2-(2-fluoro-3′-trifluoromethylbiphen-4-yl) propionic acid, 2-(2-fluoro-3′,5′-bis (trifluoromethyl) biphen-4-yl) propionic acid, 2-(4′-cyclohexyl-2-fluorobiphen-4-yl) propionic acid, 2-(2-Fluoro-1,1′-biphenyl-4-yl)-2-methylpropanoic acid, 2-Methyl-2-(3-phenoxy-phenyl)-propionic acid, 2-(4-Isobutyl-phenyl)-2-methyl-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)-2-methyl-propionic acid, 2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-2-methyl-propionic acid, and 5-[1-(2-Fluoro-biphenyl-4-yl)-1-methyl-ethyl]-2H-tetrazole, or a pharmaceutically acceptable salt or ester thereof.  
     
     
         25 . The co-formulation of  claim 23  wherein rivastigmine or a pharmaceutically acceptable salt or ester thereof is present in an amount from 3 mg to 12 mg.